Increasing fungal infections in the intensive care unit

Surgical Infections

Volumn 7, Issue SUPPL. 2, 2006, Pages

  De Pauw, Ben E ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; CASPOFUNGIN; CYCLOPHOSPHAMIDE; ECHINOCANDIN; FLUCONAZOLE; MICAFUNGIN; POLYENE ANTIBIOTIC AGENT; PURINE ANTAGONIST; PYRROLE DERIVATIVE; VORICONAZOLE;

ASPERGILLOSIS; ASPERGILLUS; CANDIDA; CANDIDIASIS; CLINICAL TRIAL; DIAGNOSTIC PROCEDURE; DRUG CHOICE; DRUG CROSS REACTIVITY; DRUG EFFICACY; DRUG SAFETY; EMPIRICISM; HUMAN; INCIDENCE; INFECTION RISK; INTENSIVE CARE UNIT; MEDICAL LITERATURE; MOULD; MYCOSIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; STANDARD; YEAST;

ANTIFUNGAL AGENTS; ASPERGILLOSIS; CANDIDIASIS; HUMANS; INCIDENCE; INTENSIVE CARE UNITS; MYCOSES;

EID: 33748084696     PISSN: 10962964     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (12)

1. Wisplinghoff H, Seifert H, Wenzel RP, Edmond MB. Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the USA. Clin Infect Dis 2003;36:1103-1110.
2. Hagen EA, Stern H, Porter D, et al. High rate of invasive fungal infections following nonmyeloablative allogeneic transplantation. Clin Infect Dis 2003;36: 9-15.
3. Blijlevens NMA, Donnelly JP, De Pauw BE. Impaired gut function as risk factor for invasive candidiasis in neutropenic patients. Br J Haematol 2002;117:259-264.
4. Viscoli C, Girmenia C, Marinus A, et al. Candidemia in cancer patients: A prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Clin Infect Dis 1999;28:1071-1079.
5. McNeil MM, Nash SL, Hajjeh RA, et al. Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997. Clin Infect Dis 2001;33:641-647.
6. Paterson DL, Singh N. Invasive aspergillosis in transplant recipients. Medicine 1999;78:123-38.
7. Nucci M, Anaissie E. Cutaneous infection by Fusarium species in healthy and immunocompromised hosts: Implications for diagnosis and management. Clin Infect Dis 2002;35:909-920.
8. Marr KA, Carter RA, Crippa F, et al. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002;34: 909-917.
9. Pfaller MA, Jones RN, Doern GV, et al. Bloodstream infections due to Candida species: SENTRY antimicrobial surveillance program in North America and Latin America, 1997-1998. Antimicrob Agents Chemother 2000;44:747-571.
10. De Pauw BE. Preventative use of antifungal drugs in patients treated for cancer. J Antimicrob Chemother 2004;53:130-132.
11. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002;347: 408-415.
12. Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002;347:2020-2029.